Determination of Gypenoside A and Gypenoside XLIX in Rat Plasma by UPLC-MS/MS and Applied to the Pharmacokinetics and Bioavailability

Table 3

Main pharmacokinetic parameters after intravenous (iv) and oral (po) administration of gypenoside A and gypenoside XLIX in rats.

Compound	Group	AUC(0-t) (ng/mL·h)	AUC(0-∞) (ng/mL·h)	t1/2z (h)	CLz/F (L/h/kg)	Vz/F (L/kg)	Cmax (ng/mL)
Gypenoside A	Po, 5 mg/kg	14.9 ± 2.4	15.9 ± 2.5	1.4 ± 0.2	319.9 ± 49.8	665.4 ± 161.4	8.6 ± 1.3
	Iv, 1 mg/kg	332.9 ± 31.2	334.3 ± 32.2	0.8 ± 0.2	3.0 ± 0.3	3.3 ± 0.7	621.9 ± 36.2
Gypenoside XLIX	Po, 5 mg/kg	13.7 ± 2.5	15.4 ± 2.2	1.8 ± 0.6	330.8 ± 52.7	879.8 ± 345.0	8.1 ± 0.9
	Iv, 1 mg/kg	1923.5 ± 62.5	1926.6 ± 62.3	1.6 ± 1.7	0.52 ± 0.02	1.2 ± 1.3	2201.9 ± 211.6